Quick Links



2014-04-15 - Kathleen Hoffman
2014-10-14 - Howard Elman


2013-03-12 - Harsh Jain


Tuesday, March 12, 2013
316 Stanley Thomas Hall
Tulane University (Uptown)

Refreshments will be served


Harsh Jain, Florida State University, Department of Mathematics


Models of anti-androgen therapy for the treatment of prostate cancer


Due to its dependence on androgens, advanced prostate cancer is typically treated with continuous androgen ablation. However, such therapy eventually fails due to the emergence of castration-resistance cells. It has been hypothesized that intermittent androgen ablation can delay the onset of this resistance. In this talk, I will present a  biochemically-motivated mathematical model of prostate cancer response to anti-androgen therapy, with the aim of predicting optimal treatment protocols based on individual patient characteristics. The model is derived using ordinary and partial differential equations, and validated versus available clinical data. The model predicts that intermittent scheduling is preferable over continuous therapy only for specific castration-resistant cell phenotypes, namely, androgen-repressed cells, and androgen-independent cells that compete poorly with androgen-dependent cells for resources. In all other cases, continuous therapy results in longer disease-free survival periods. These results are also proven analytically. Further, simulation and analysis of the model indicates that cancer cell proliferation and mitotic indices and PSA expression levels are important markers of disease significance and useful in predicting patient response to therapy. Finally, a PDE version of the model is developed, and existence and uniqueness results derived for the resulting free boundary problem. These results are illustrated with numerical simulations of a tumor growing in 2-dimensions with radial symmetry.

Center for Computational Science, Stanley Thomas Hall 402, New Orleans, LA 70118